- Quantitative analysis of enhanced malignant and benign lesions on contrast-enhanced spectral mammography. [Journal Article]
- BJBr J Radiol 2018 Feb 16; :20170605
- CONCLUSIONS: Despite variations in the degree of tumoural angiogenesis, quantitative analysis of the breast lesions on CESM documented the malignancies had distinctive stronger enhancement and depressed relative enhancement patterns than benign lesions. Advances in Knowledge: To our knowledge, this is the first study evaluating the feasibility of quantifying lesion enhancement on CESM. The quantities of enhancement were informative for assessing breast lesions in which the malignancies had stronger enhancement and more relative depressed enhancement than the benign lesions.
- Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. [Journal Article]
- BJBr J Radiol 2018 Feb 16; :20170498
- CONCLUSIONS: This study provides proof of concept that molecular information can be derived from standard medical images and shows potential for radiomics as imaging biomarker of HPV status. Advances in knowledge: Radiomics has the potential to identify clinically relevant molecular phenotypes.
- Vacuum assisted breast biopsy (VAB) excision of subcentimeter microcalcifications as an alternative to open biopsy for atypical ductal hyperplasia. [Journal Article]
- BJBr J Radiol 2018 Feb 16; :20180003
- CONCLUSIONS: These results could justify the conservative management, in a selected group of patients, being the malignancy rate lower than 2%, considered in the literature as the "probably benign" definition. Advances in knowledge: Increasing the length of follow-up of selected patients conservatively managed can improve the management of ADH cases.
- Hepatocellular carcinoma surveillance with ultrasound-cost effectiveness, high-risk populations, uptake. [Journal Article]
- BJBr J Radiol 2018 Feb 15; :20170436
- Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second cause of cancer-related deaths worldwide. In most cases, it is diagnosed in patients with identified risk facto...
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second cause of cancer-related deaths worldwide. In most cases, it is diagnosed in patients with identified risk factors, mainly cirrhosis from all causes. These patients are candidates for a surveillance program that, depending on guidelines, involves regular liver ultrasound alone or combined with serum markers. These programs have been shown to improve the oncological outcome by detecting earlier stage tumors and providing patients with potentially curative treatment and improved survival. Yet, the level of evidence supporting these guidelines remain limited. This review article presents an overview of the evidence supporting surveillance programs for HCC, in particular the efficacy, cost-effectiveness, and consequences of this approach for patient survival. Western and Eastern guideline recommendations are described and discussed.
- Dual-energy CT iodine maps as an alternative quantitative imaging biomarker to abdominal CT perfusion: determination of appropriate trigger delays for acquisition using bolus tracking. [Journal Article]
- BJBr J Radiol 2018 Feb 15; :20170351
- CONCLUSIONS: An acquisition window between 15-21s after exceeding bolus tracking threshold shows promising results for acquisition of DECT iodine maps as an alternative to CT-perfusion measurements of BF. Advances in knowledge: After clinical validation, DECT iodine maps of pancreas acquired using bolus tracking with appropriate trigger delay as determined in this study could offer an alternative quantitative imaging biomarker providing functional information for tumor assessment at reduced patient radiation exposure compared to CT-perfusion measurements of BF.
- Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. [Journal Article]
- BJBr J Radiol 2018 Feb 15; :20170737
- CONCLUSIONS: The credentialing process documented that participating centres were able to deliver dose as required in the trial protocol. It also gave an opportunity to provide education about the trial and discuss technical issues such as 4DCT, small field dosimetry and patient immobilisation with staff in participating centres. Advances in knowledge: Credentialing is an important quality assurance tool for radiotherapy trials using advanced technology. In addition to confirming technical competence it provides an opportunity for education and discussion about the trial.
- Comparing photon and proton based hypofractioned sbrt for prostate cancer accounting for robustness and realistic treatment deliverability. [Journal Article]
- BJBr J Radiol 2018 Feb 13; :20180010
- CONCLUSIONS: Similar treatment plans can be generated with IMPT compared to VMAT in terms of target coverage, target conformality, and OAR sparing when range and HU uncertainties are neglected. However, when accounting for these uncertainties during robust optimization, VMAT outperforms IMPT in terms of achievable target conformity and OAR sparing. Advances in knowledge: Comparison between achievable dose distributions using modern, robust optimization of IMPT for high dose per fraction SBRT regimens for the prostate has not been previously investigated.
- Mammography cancer detection: comparison of single 8MP and pair of 5MP reporting monitors. [Journal Article]
- BJBr J Radiol 2018 Feb 13; :20170246
- CONCLUSIONS: Providing quadrant view is used in addition to full field view, there is no significant difference in cancer detection between the 8MP monitor and the pair of 5MP monitors. Advances in knowledge: Effect of magnification on the detectability of subtle malignant calcification clusters in breast screening.
- Image-guided biopsy of small (≤ 4cm) renal masses: the effect of size and anatomical location on biopsy success rate and complications. [Journal Article]
- BJBr J Radiol 2018 Feb 13; :20170666
- Objective To study the influence of tumour diameter and anatomy on the success and complication rates of small renal mass (SRM,≤4 cm) core biopsy Methods Retrospective analysis of SRMs that underwent...
Objective To study the influence of tumour diameter and anatomy on the success and complication rates of small renal mass (SRM,≤4 cm) core biopsy Methods Retrospective analysis of SRMs that underwent ultrasound or computed tomography-(CT) guided biopsy. Diagnostic and complication rates were compared according to tumour size (sub-categorised as axial diameter ≤2 cm,>2 to≤3 cm,>3 to≤4 cm) and anatomical disposition (exophytic/endophytic, centrality, polar location and anterior/posterior). Results Ninety-four patients (54 male; age range 21.8-84.3 years) with 95 SRMs underwent biopsy. The first biopsy was diagnostic in 81/95 (85.3%). Seven patients underwent repeat biopsy (6/7 diagnostic), to give an overall diagnostic rate of 91.5%. The primary diagnostic rates in the ≤2,>2 to≤3,>3 to≤4 cm groups were 21/25 (84%); 38/44 (86.4%) and 22/26 (84.6%) respectively and were similar (p = 1.00). Anterior and upper pole SRMs were more likely to fail initial biopsy (odds ratio (OR) 13.8, p < 0.01; and OR 4.35, p = 0.04) respectively, but other anatomical factors were not relevant. Complications occurred in 14% (all conservatively managed perinephric haematomas; Clavien-Dindo Grade 1) and size or location were not relevant. Conclusions Image-guided biopsy of SRMs has a high diagnostic rate irrespective of tumour size. Anterior and upper pole location had lower diagnostic rates. Biopsy should be considered for all patients with SRMs if the result will impact on management and we list specific scenarios where an SRM biopsy may be helpful. Advances in knowledge SRM size does not affect the likelihood of a diagnostic biopsy.
New Search Next
- Targeting tumour hypoxia: shifting focus from oxygen supply to demand. [Journal Article]
- BJBr J Radiol 2018 Feb 13; :20170843
- Tumour hypoxia is a well-recognised barrier to anti-cancer therapy and represents one of the best validated targets in oncology. Previous attempts to tackle hypoxia have focussed primarily on increas...
Tumour hypoxia is a well-recognised barrier to anti-cancer therapy and represents one of the best validated targets in oncology. Previous attempts to tackle hypoxia have focussed primarily on increasing tumour oxygen supply; however, clinical studies using this approach have yielded only modest clinical benefit, with often significant toxicity and practical limitations. Therefore, there are currently no anti-hypoxia treatments in widespread clinical use. As an emerging alternative strategy, we discuss the relevance of inhibiting tumour oxygen metabolism to alleviate hypoxia and highlight recently initiated clinical trials using this approach.